Home Cart Sign in  
Chemical Structure| 14892-97-8 Chemical Structure| 14892-97-8

Structure of SCR7 pyrazine
CAS No.: 14892-97-8

Chemical Structure| 14892-97-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SCR7 pyrazine is a specific DNA ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

Synonyms: SCR7

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SCR7 pyrazine

CAS No. :14892-97-8
Formula : C18H12N4OS
M.W : 332.38
SMILES Code : O=C1NC(NC2=NC(C3=CC=CC=C3)=C(C4=CC=CC=C4)N=C12)=S
Synonyms :
SCR7
MDL No. :MFCD02167478
InChI Key :GSRTWXVBHGOUBU-UHFFFAOYSA-N
Pubchem ID :10688007

Safety of SCR7 pyrazine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of SCR7 pyrazine

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 cells 0.01 μM 24 hours In the presence of 0.01 μM Scr7, the insertion efficiency at the target site in A549 cells was improved ~3-fold compared to the untreated control PMC5030191
MelJuSo cells 0.01 μM to 1 μM 24 hours Scr7 treatment significantly enhanced the insertion efficiency in MelJuSo cells, up to 19-fold PMC4618510
DC2.4 cells 1 μM 24 hours Scr7 treatment improved the insertion efficiency at the target site in DC2.4 cells by ~13-fold PMC4008238
human kidney organoids 1 μM 24 hours SCR7 inhibits DNA ligase IV, partially reversing kidney organoid atrophy and rescuing FANCD2 expression in DNA damaged tubular cells. PMC9161367
N-thy-ori-3-1 cells 50 µM 1 hour Inhibit the NHEJ repair pathway, reduce IR-induced RET/PTC1 rearrangement PMC11318340
MCF-7 cells 10-80 μM 48 hours SCR7 significantly enhanced ssODN-directed targeted insertion efficiency in MCF-7 and HCT-116 cells and reduced the NHEJ rate. PMC5819182
HCT-116 cells 5-40 μM 48 hours SCR7 significantly enhanced ssODN-directed targeted insertion efficiency in HCT-116 cells and reduced the NHEJ rate. PMC5819182
HEK293T cells 1 µM 72 hours SCR7 increased HDR efficiency, with a ~1.5-fold increase in the number of GFP+ cells and a 1.6–1.8-fold increase in the number of corrected alleles. PMC4941640

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice fertilized zygotes cytoplasmic injection 20 mg/kg Every other day for one month Co-injection of Scr7 significantly improved the efficiency of HDR-mediated insertional mutagenesis, with the insertion efficiency of the Kell gene increasing from 26.8% to 59.3% PMC4618510

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.01mL

0.60mL

0.30mL

15.04mL

3.01mL

1.50mL

30.09mL

6.02mL

3.01mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories